Anti-CD30 antibody–drug conjugate brentuximab vedotin and immune check point inhibitors (nivolumab, pembrolizumab) have been approved for salvage therapy of R/R HL [12,13,14]. Here, TNFRSF8 is linked to Hodgkins lymphoma.